



Welcome to the Ferring Innovation Grants Portal from Ferring Research Institute, Inc., (FRI).  
The Ferring Innovation Grants are awarded once each year and are not renewable.

### **Ferring Innovation Grant Overview:**

#### **What is of Interest to Ferring**

FRI is interested in funding exploratory, discovery and preclinical research into novel drug targets and biomarkers with potential application in specific indications within the following core therapeutic areas:

- Gastroenterology & Hepatology
- Reproductive Medicine and Women's Health
- Urology

#### **What the program will not fund**

The following types of studies are beyond the scope of the program:

- Clinical studies
- Studies which require the collection of human samples under the direction of an Institutional Review Board

#### **Available Funding**

- The program will provide a limited number of research grants: Funding levels will range from \$50,000 to \$100,000.
- Reasonable indirect costs can be included for consideration as part of the research award.

#### **Intellectual Property**

Intellectual property ownership shall be determined in accordance with U.S. patent and copyright laws, and may be subject to the policies of the research grant recipient's institution.

Prior to funding of the research grant, the recipient and a designated representative of the recipient's institution must execute an agreement (Ferring Innovation Grants Agreement), which sets forth intellectual property rights, publication, and other requirements relevant to the proposed research.

### **Application Process and Requirements:**

#### **Application Process**

- Applicants are required to submit a pre-application.
- Reasonable indirect costs can now be included for consideration in addition to the research grant award.
- Applicants will receive a confirmation email notification after submitting a completed application.
- Requests for clarification, additional information or modification will be sent to the applicant via email.
- Ferring will give careful consideration to all eligible requests based on relevance to our guidelines, merit and available resources.
- Previous funding is not an indicator of future support.
- Applicants will be notified via email within 4 weeks of the submission deadline regarding the outcome of their application.
- Successful applicants will be provided with a target budget and a link to re-enter the grant portal to submit a full proposal.
- Full proposals must be submitted within 4 weeks of notification
- Research grant recipients will be notified within 4 weeks of the submission deadline.
- Ferring Innovation Grants will be funded for research projects to be completed within one year commencing on January 1st.

## Pre-Application Requirements

The pre-application process has been designed for ease of use and requires the following information:

- Investigator name, title and affiliation
- Type of research grant requested
- Title (20 words): The title should contain sufficient information to enable the reviewer to clearly identify the therapeutic area and proposed target.
- Brief overview of project (200 words): In this section please provide the background supporting the scientific hypothesis.
- Scientific rationale and aims of the project (500 words): In this section please provide the scientific rationale for your hypothesis and 2-3 specific aims proposed to test the hypothesis, along with a summary of the potential application of the findings.
- Institution's percentage indirect cost, if applicable
- Upload a current résumé.
- Information provided in the pre-application must be non-confidential in nature.

## Full Proposal Requirements

The full proposal must include:

- Scientific rationale and aims (550 words): In this section please provide the scientific rationale for your hypothesis (150 words). Describe in detail 2 to 3 aims of the project that will be used to test your hypothesis and that can be completed in a 12 month period (400 words).
- Detailed experimental outline for each individual aim (1500 words): In this section describe in detail the experiment(s) you propose to carry out over the 12 month funding period to address each individual aim (1,200 words), along with expected outcome and potential application of the findings (300 words).
- Work plan with a timeline
- Detailed budget
- Two additional supportive documents may also be uploaded.

Research grant recipients will be notified within 4 weeks of the submission deadline.

Ferring Innovation Grants will be funded for research projects to be completed within one year commencing in January.

Intellectual property ownership shall be determined in accordance with U.S. patent and copyright laws, and may be subject to the policies of the research grant recipient's institution.

Prior to funding of the research grant, the recipient and a designated representative of the recipient's institution must execute an agreement (Ferring Innovation Grants Agreement), which sets forth intellectual property rights, publication, and other requirements relevant to the proposed research.

## Budget Guidelines

Ferring Innovation Grants requests must be limited to a reasonable estimate of the cost of the grant-funded activities. Please complete the Budget form provided.

Listed below are expenses Ferring shall not support:

- Lavish venues and meals
- Travel, lodging, honoraria, registration, compensation or individual expenses for attendees
- Entertainment
- Contingency/unspecified expense line items
- Gifts
- Other costs that are neither reasonable nor customary

## Reports

Ferring Innovation Grants recipients will be required to provide two status reports during the funding period. A Progress Report is due within 30 days following completion of the first 6 months of the project. It must be submitted using the Progress Report form that can be downloaded from the FRI website.

The Final Report is due within 30 days of the end of the funding period. It must be submitted using the Final Report form that can be downloaded from the FRI website.

## Change in Scope

Ferring Innovation Grants recipients will be required to notify Ferring of any changes that may impact their ability to perform the work outline in their proposal. For example: change in institution of employment, a change in their employment status, or unforeseen technical difficulties.

## Important Information Relating to the Ferring Research Institute Innovation Grants Process

- Support is based on individual merit relative to other grant requests in accordance with established guidelines and policies and will not be provided to induce the provision of services or promote, sell or prescribe a Ferring product.
- Ferring is unable to provide support for every request and may not be able to fund the entire requested amount.
- Previous support does not guarantee future support.
- Previously declined programs are not eligible for re-submission.
- Please do not submit requests that include funding for promotional programs, membership fees, sponsorships, medical missions, ads, medication, equipment or tuition.
- Please do not submit requests for exhibit/display booths, charitable contributions, promotional programs, membership fees, sponsorships, social events/entertainment, medical missions, ads, medication, equipment, tuition, or for non-faculty personnel or individual attendee expenses.

Ferring's support may never be made with the intent to, directly or indirectly, implicitly or explicitly, influence recipients to prescribe, purchase, recommend, sell or arrange for, or recommend the prescribing, purchasing or sale of any Ferring product or as a reward for any such past behavior.

## Financial Disclosure

The Centers for Medicare & Medicaid Services (CMS) has issued its final rule to implement the Federal Physician Payments Sunshine Act (Open Payments). The Sunshine Act requires pharmaceutical and device manufacturers to annually report certain payments or other transfers of value made to "Covered Recipients," including US-licensed physicians and teaching hospitals. The Sunshine Act promotes transparency by requiring the disclosure of financial relationships between drug manufacturers, investigators and study sites.